Tocotrienol supports liver health
In a clinical trial conducted by Sanyal, et al on patients with non-alcoholic steatohepatitis (NASH), treatment with alpha tocopherol Vitamin E resulted in significant improvement in NASH as compared to the antidiabetes drug pioglitazone (43% vs 19%) and placebo. 
Oral intake of palm tocotrienol demonstrated improvement in the fatty liver conditions of human subjects in a recent double-blind, placebo-controlled trial. In this study conducted by Magosso et al, 69% of the subjects with non-alcoholic fatty liver disease (NAFLD) on palm tocotrienol showed improvement in their liver imaging test results as compared to 33% in the placebo group. 
Read Top Articles
1. Kiec-Wilk B, Klupa T and Dembinska-Kiec A. Non-alcoholic fatty liver disease (NAFLD) in patients with metabolic syndrome and type 2 diabetes mellitus. Pathomechanism, new diagnostic markers. Przegl Lek, 2010:67(7):496-501.
2. Youssoni Z, et al. The Changing Face of Chronic Liver Disease (CLD) in the United States: The Rising Epidemic of Non-Alcoholic Fatty Liver Disease (NAFLD). Presented at The International Liver Congress 2011.
3. Ahmed M H, Abu E O, and Byrne C D.Non-Alcoholic Fatty Liver Disease (NAFLD): new challenge for general practitioners and important burden for health authorities? Prim Care Diabetes, 2010;4(3):129-37.
4. Sanyal A J, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med, 2010;362(18):1675-85.
5. Magosso EA, et al. Presented in the 61st Annual Meeting of the American Association for the Study of Liver Disease (AASLD) The Liver Meeting®. 2012: Boston, USA.